Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Vernon Holers to Receptors, Complement

This is a "connection" page, showing publications Vernon Holers has written about Receptors, Complement.

 
Connection Strength
 
 
 
5.380
 
  1. Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol. 2014; 32:433-59.
    View in: PubMed
    Score: 0.440
  2. Banda NK, Hyatt S, Antonioli AH, White JT, Glogowska M, Takahashi K, Merkel TJ, Stahl GL, Mueller-Ortiz S, Wetsel R, Arend WP, Holers VM. Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J Immunol. 2012 Feb 01; 188(3):1469-78.
    View in: PubMed
    Score: 0.381
  3. Thurman JM, Ljubanovic D, Royer PA, Kraus DM, Molina H, Barry NP, Proctor G, Levi M, Holers VM. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest. 2006 Feb; 116(2):357-68.
    View in: PubMed
    Score: 0.253
  4. Holers VM. Complement receptors and the shaping of the natural antibody repertoire. Springer Semin Immunopathol. 2005 Mar; 26(4):405-23.
    View in: PubMed
    Score: 0.234
  5. Kang HJ, Bao L, Xu Y, Quigg RJ, Giclas PC, Holers VM. Increased serum C3 levels in Crry transgenic mice partially abrogates its complement inhibitory effects. Clin Exp Immunol. 2004 May; 136(2):194-9.
    View in: PubMed
    Score: 0.224
  6. Fleming SD, Shea-Donohue T, Guthridge JM, Kulik L, Waldschmidt TJ, Gipson MG, Tsokos GC, Holers VM. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol. 2002 Aug 15; 169(4):2126-33.
    View in: PubMed
    Score: 0.199
  7. Quigg RJ, He C, Lim A, Berthiaume D, Alexander JJ, Kraus D, Holers VM. Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury. J Exp Med. 1998 Oct 05; 188(7):1321-31.
    View in: PubMed
    Score: 0.152
  8. Quigg RJ, Kozono Y, Berthiaume D, Lim A, Salant DJ, Weinfeld A, Griffin P, Kremmer E, Holers VM. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol. 1998 May 01; 160(9):4553-60.
    View in: PubMed
    Score: 0.148
  9. Antonioli AH, White J, Crawford F, Renner B, Marchbank KJ, Hannan JP, Thurman JM, Marrack P, Holers VM. Modulation of the Alternative Pathway of Complement by Murine Factor H-Related Proteins. J Immunol. 2018 01 01; 200(1):316-326.
    View in: PubMed
    Score: 0.144
  10. Laskowski J, Renner B, Le Quintrec M, Panzer S, Hannan JP, Ljubanovic D, Ruseva MM, Borza DB, Antonioli AH, Pickering MC, Holers VM, Thurman JM. Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. Kidney Int. 2016 07; 90(1):109-22.
    View in: PubMed
    Score: 0.129
  11. Quigg RJ, Holers VM. Characterization of rat complement receptors and regulatory proteins. CR2 and Crry are conserved, and the C3b receptor of neutrophils and platelets is distinct from CR1. J Immunol. 1995 Aug 01; 155(3):1481-8.
    View in: PubMed
    Score: 0.122
  12. Kozono Y, Duke RC, Schleicher MS, Holers VM. Co-ligation of mouse complement receptors 1 and 2 with surface IgM rescues splenic B cells and WEHI-231 cells from anti-surface IgM-induced apoptosis. Eur J Immunol. 1995 Apr; 25(4):1013-7.
    View in: PubMed
    Score: 0.119
  13. Atkinson C, Qiao F, Yang X, Zhu P, Reaves N, Kulik L, Goddard M, Holers VM, Tomlinson S. Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation. 2015 Mar 31; 131(13):1171-80.
    View in: PubMed
    Score: 0.118
  14. Kim YU, Kinoshita T, Molina H, Hourcade D, Seya T, Wagner LM, Holers VM. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med. 1995 Jan 01; 181(1):151-9.
    View in: PubMed
    Score: 0.117
  15. Li B, Sallee C, Dehoff M, Foley S, Molina H, Holers VM. Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol. 1993 Oct 15; 151(8):4295-305.
    View in: PubMed
    Score: 0.108
  16. Foley S, Li B, Dehoff M, Molina H, Holers VM. Mouse Crry/p65 is a regulator of the alternative pathway of complement activation. Eur J Immunol. 1993 Jun; 23(6):1381-4.
    View in: PubMed
    Score: 0.105
  17. Holers VM, Kinoshita T, Molina H. The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. Immunol Today. 1992 Jun; 13(6):231-6.
    View in: PubMed
    Score: 0.098
  18. Krych M, Atkinson JP, Holers VM. Complement receptors. Curr Opin Immunol. 1992 Feb; 4(1):8-13.
    View in: PubMed
    Score: 0.096
  19. Molina H, Wong W, Kinoshita T, Brenner C, Foley S, Holers VM. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med. 1992 Jan 01; 175(1):121-9.
    View in: PubMed
    Score: 0.095
  20. Molina H, Brenner C, Jacobi S, Gorka J, Carel JC, Kinoshita T, Holers VM. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction. J Biol Chem. 1991 Jul 05; 266(19):12173-9.
    View in: PubMed
    Score: 0.092
  21. Rayhel EJ, Dehoff MH, Holers VM. Characterization of the human complement receptor 2 (CR2, CD21) promoter reveals sequences shared with regulatory regions of other developmentally restricted B cell proteins. J Immunol. 1991 Mar 15; 146(6):2021-6.
    View in: PubMed
    Score: 0.090
  22. Molina H, Kinoshita T, Inoue K, Carel JC, Holers VM. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J Immunol. 1990 Nov 01; 145(9):2974-83.
    View in: PubMed
    Score: 0.088
  23. Renner B, Coleman K, Goldberg R, Amura C, Holland-Neidermyer A, Pierce K, Orth HN, Molina H, Ferreira VP, Cortes C, Pangburn MK, Holers VM, Thurman JM. The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J Immunol. 2010 Sep 01; 185(5):3086-94.
    View in: PubMed
    Score: 0.086
  24. Carel JC, Myones BL, Frazier B, Holers VM. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J Biol Chem. 1990 Jul 25; 265(21):12293-9.
    View in: PubMed
    Score: 0.086
  25. Carel JC, Frazier B, Ley TJ, Holers VM. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells. J Immunol. 1989 Aug 01; 143(3):923-30.
    View in: PubMed
    Score: 0.081
  26. Fujisaku A, Harley JB, Frank MB, Gruner BA, Frazier B, Holers VM. Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor. J Biol Chem. 1989 Feb 05; 264(4):2118-25.
    View in: PubMed
    Score: 0.078
  27. Holers VM. Complement receptors. Year Immunol. 1989; 4:231-40.
    View in: PubMed
    Score: 0.077
  28. Hourcade D, Miesner DR, Atkinson JP, Holers VM. Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1. J Exp Med. 1988 Oct 01; 168(4):1255-70.
    View in: PubMed
    Score: 0.076
  29. Song H, Qiao F, Atkinson C, Holers VM, Tomlinson S. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol. 2007 Dec 01; 179(11):7860-7.
    View in: PubMed
    Score: 0.072
  30. Holers VM, Chaplin DD, Leykam JF, Gruner BA, Kumar V, Atkinson JP. Human complement C3b/C4b receptor (CR1) mRNA polymorphism that correlates with the CR1 allelic molecular weight polymorphism. Proc Natl Acad Sci U S A. 1987 Apr; 84(8):2459-63.
    View in: PubMed
    Score: 0.069
  31. Leinhase I, Schmidt OI, Thurman JM, Hossini AM, Rozanski M, Taha ME, Scheffler A, John T, Smith WR, Holers VM, Stahel PF. Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Exp Neurol. 2006 Jun; 199(2):454-64.
    View in: PubMed
    Score: 0.064
  32. Holers VM, Seya T, Brown E, O'Shea JJ, Atkinson JP. Structural and functional studies on the human C3b/C4b receptor (CR1) purified by affinity chromatography using a monoclonal antibody. Complement. 1986; 3(2):63-78.
    View in: PubMed
    Score: 0.063
  33. Ohta R, Kondor N, Dohi N, Tomlinson S, Imai M, Holers VM, Okada H, Okada N. Mouse complement receptor-related gene y/p65-neutralized tumor vaccine induces antitumor activity in vivo. J Immunol. 2004 Jul 01; 173(1):205-13.
    View in: PubMed
    Score: 0.057
  34. M?hlfeld AS, Segerer S, Hudkins K, Farr AG, Bao L, Kraus D, Holers VM, Quigg RJ, Alpers CE. Overexpression of complement inhibitor Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis. Kidney Int. 2004 Apr; 65(4):1214-23.
    View in: PubMed
    Score: 0.056
  35. Park JW, Taube C, Joetham A, Takeda K, Kodama T, Dakhama A, McConville G, Allen CB, Sfyroera G, Shultz LD, Lambris JD, Giclas PC, Holers VM, Gelfand EW. Complement activation is critical to airway hyperresponsiveness after acute ozone exposure. Am J Respir Crit Care Med. 2004 Mar 15; 169(6):726-32.
    View in: PubMed
    Score: 0.055
  36. Alexander JJ, Bao L, Jacob A, Kraus DM, Holers VM, Quigg RJ. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis. Biochim Biophys Acta. 2003 Nov 20; 1639(3):169-76.
    View in: PubMed
    Score: 0.054
  37. Taube C, Rha YH, Takeda K, Park JW, Joetham A, Balhorn A, Dakhama A, Giclas PC, Holers VM, Gelfand EW. Inhibition of complement activation decreases airway inflammation and hyperresponsiveness. Am J Respir Crit Care Med. 2003 Dec 01; 168(11):1333-41.
    View in: PubMed
    Score: 0.054
  38. Banda NK, Kraus DM, Muggli M, Bendele A, Holers VM, Arend WP. Prevention of collagen-induced arthritis in mice transgenic for the complement inhibitor complement receptor 1-related gene/protein y. J Immunol. 2003 Aug 15; 171(4):2109-15.
    View in: PubMed
    Score: 0.053
  39. Aslam M, Guthridge JM, Hack BK, Quigg RJ, Holers VM, Perkins SJ. The extended multidomain solution structures of the complement protein Crry and its chimeric conjugate Crry-Ig by scattering, analytical ultracentrifugation and constrained modelling: implications for function and therapy. J Mol Biol. 2003 Jun 06; 329(3):525-50.
    View in: PubMed
    Score: 0.053
  40. Holers VM. The complement system as a therapeutic target in autoimmunity. Clin Immunol. 2003 Jun; 107(3):140-51.
    View in: PubMed
    Score: 0.053
  41. Fahnoe KC, Liu F, Morgan JG, Ryan ST, Storek M, Stark EG, Taylor FR, Holers VM, Thurman JM, Wawersik S, Kalled SL, Violette SM. Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue. Front Immunol. 2022; 13:869725.
    View in: PubMed
    Score: 0.049
  42. Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, Alexander JJ, Anderson RK, Culhane K, Holers VM, Quigg RJ. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol. 2002 Apr 01; 168(7):3601-7.
    View in: PubMed
    Score: 0.048
  43. Rehrig S, Fleming SD, Anderson J, Guthridge JM, Rakstang J, McQueen CE, Holers VM, Tsokos GC, Shea-Donohue T. Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J Immunol. 2001 Nov 15; 167(10):5921-7.
    View in: PubMed
    Score: 0.047
  44. Schiller B, Cunningham PN, Alexander JJ, Bao L, Holers VM, Quigg RJ. Expression of a soluble complement inhibitor protects transgenic mice from antibody-induced acute renal failure. J Am Soc Nephrol. 2001 Jan; 12(1):71-79.
    View in: PubMed
    Score: 0.044
  45. Holers VM. Phenotypes of complement knockouts. Immunopharmacology. 2000 Aug; 49(1-2):125-31.
    View in: PubMed
    Score: 0.043
  46. Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H. A critical role for murine complement regulator crry in fetomaternal tolerance. Science. 2000 Jan 21; 287(5452):498-501.
    View in: PubMed
    Score: 0.042
  47. Davoust N, Nataf S, Holers VM, Barnum SR. Expression of the murine complement regulatory protein crry by glial cells and neurons. Glia. 1999 Aug; 27(2):162-70.
    View in: PubMed
    Score: 0.040
  48. Nardin A, Schlimgen R, Holers VM, Taylor RP. A prototype pathogen bound ex vivo to human erythrocyte complement receptor 1 via bispecific monoclonal antibody complexes is cleared to the liver in a mouse model. Eur J Immunol. 1999 05; 29(5):1581-6.
    View in: PubMed
    Score: 0.040
  49. Alexander JJ, Lim A, He C, MacDonald RL, Holers VM, Quigg RJ. Renal, central nervous system and pancreatic overexpression of recombinant soluble Crry in transgenic mice. A novel means of protection from complement-mediated injury. Immunopharmacology. 1999 May; 42(1-3):245-54.
    View in: PubMed
    Score: 0.040
  50. Quigg RJ, Morgan BP, Holers VM, Adler S, Sneed AE, Lo CF. Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells. Kidney Int. 1995 Aug; 48(2):412-21.
    View in: PubMed
    Score: 0.031
  51. Quigg RJ, Holers VM, Morgan BP, Sneed AE. Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J Immunol. 1995 Apr 01; 154(7):3437-43.
    View in: PubMed
    Score: 0.030
  52. Graham IL, Anderson DC, Holers VM, Brown EJ. Complement receptor 3 (CR3, Mac-1, integrin alpha M beta 2, CD11b/CD18) is required for tyrosine phosphorylation of paxillin in adherent and nonadherent neutrophils. J Cell Biol. 1994 Nov; 127(4):1139-47.
    View in: PubMed
    Score: 0.029
  53. Carel JC, Holers VM, Chick WL, Littman D, Lacy PE. Expression of functional human Epstein-Barr virus/C3d receptor ([CR2] CD21) on insulinoma cell line. Induction of tumor rejection but not diabetes in syngeneic rats. Diabetes. 1991 Jul; 40(7):809-14.
    View in: PubMed
    Score: 0.023
  54. Thurman JM, Renner B, Kunchithapautham K, Holers VM, Rohrer B. Aseptic injury to epithelial cells alters cell surface complement regulation in a tissue specific fashion. Adv Exp Med Biol. 2010; 664:151-8.
    View in: PubMed
    Score: 0.021
  55. Van Dyne S, Holers VM, Lublin DM, Atkinson JP. The polymorphism of the C3b/C4b receptor in the normal population and in patients with systemic lupus erythematosus. Clin Exp Immunol. 1987 Jun; 68(3):570-9.
    View in: PubMed
    Score: 0.017
  56. Nickells MW, Seya T, Holers VM, Atkinson JP. Analysis of C3b/C4b receptor (CR1) polymorphic variants by tryptic peptide mapping. Mol Immunol. 1986 Jun; 23(6):661-8.
    View in: PubMed
    Score: 0.016
  57. Seya T, Holers VM, Atkinson JP. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF). J Immunol. 1985 Oct; 135(4):2661-7.
    View in: PubMed
    Score: 0.015
  58. Atkinson C, Song H, Lu B, Qiao F, Burns TA, Holers VM, Tsokos GC, Tomlinson S. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005 Sep; 115(9):2444-53.
    View in: PubMed
    Score: 0.015
  59. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, Takahashi K, Holers VM, Walport M, Gerard C, Ezekowitz A, Carroll MC, Brenner M, Weissleder R, Verbeek JS, Duchatelle V, Degott C, Benoist C, Mathis D. Arthritis critically dependent on innate immune system players. Immunity. 2002 Feb; 16(2):157-68.
    View in: PubMed
    Score: 0.012
  60. Cunningham PN, Holers VM, Alexander JJ, Guthridge JM, Carroll MC, Quigg RJ. Complement is activated in kidney by endotoxin but does not cause the ensuing acute renal failure. Kidney Int. 2000 Oct; 58(4):1580-7.
    View in: PubMed
    Score: 0.011
  61. Sawant-Mane S, Piddlesden SJ, Morgan BP, Holers VM, Koski CL. CD59 homologue regulates complement-dependent cytolysis of rat Schwann cells. J Neuroimmunol. 1996 Sep; 69(1-2):63-71.
    View in: PubMed
    Score: 0.008
  62. Dunster LM, Schneider-Schaulies J, Dehoff MH, Holers VM, Schwartz-Albiez R, ter Meulen V. Moesin, and not the murine functional homologue (Crry/p65) of human membrane cofactor protein (CD46), is involved in the entry of measles virus (strain Edmonston) into susceptible murine cell lines. J Gen Virol. 1995 Aug; 76 ( Pt 8):2085-9.
    View in: PubMed
    Score: 0.008
  63. Moulds JM, Krych M, Holers VM, Liszewski MK, Atkinson JP. Genetics of the complement system and rheumatic diseases. Rheum Dis Clin North Am. 1992 Nov; 18(4):893-914.
    View in: PubMed
    Score: 0.006
  64. Bora NS, Lublin DM, Kumar BV, Hockett RD, Holers VM, Atkinson JP. Structural gene for human membrane cofactor protein (MCP) of complement maps to within 100 kb of the 3' end of the C3b/C4b receptor gene. J Exp Med. 1989 Feb 01; 169(2):597-602.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)